06

February

2023

|

ten:fifty nine AM

Europe/Amsterdam

Not meant for U.S. and British isles Media

Summary

Submitting for aflibercept 8 mg in neovascular (damp) age-linked macular degeneration (nAMD) and diabetic macular edema (DME) is based mostly on favourable outcomes of medical trials, PULSAR and PHOTON / In each trials, aflibercept eight mg shown unparalleled sturdiness success with treatment method intervals of up to sixteen weeks, with comparable visible acuity as effectively as speedy and resilient fluid regulate to the comparator EyleaTM (aflibercept two mg) by way of to 7 days 48 / Protection of aflibercept eight mg was regular with the basic safety profile of Eylea (aflibercept 2 mg) / Extended procedure intervals with fewer injections into the eye in nAMD and DME fulfill an critical client will need